Montaner JSG - Search Results

1

A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015.

Olding M, Enns B, Panagiotoglou D, Shoveller J, Harrigan PR, Barrios R, Kerr T, Montaner JSG, Nosyk B. Olding M, et al. Among authors: montaner jsg. J Int AIDS Soc. 2017 Sep 19;20(1):21941. doi: 10.7448/IAS.20.1.21941. J Int AIDS Soc. 2017. PMID: 28953322 Free PMC article. Review.

2

The T cell receptor V beta repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection.

Grant M, Pardoe I, Whaley M, Montaner JS, Harrigan PR. Grant M, et al. AIDS. 2002 Jan 25;16(2):287-90. doi: 10.1097/00002030-200201250-00019. AIDS. 2002. PMID: 11807314

3

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.

Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS. Côté HC, et al. N Engl J Med. 2002 Mar 14;346(11):811-20. doi: 10.1056/NEJMoa012035. N Engl J Med. 2002. PMID: 11893792 Free article.

4

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.

Wood E, Tyndall MW, Spittal PM, Li K, Hogg RS, Montaner JS, O'Shaughnessy MV, Schechter MT. Wood E, et al. AIDS. 2002 Apr 12;16(6):941-3. doi: 10.1097/00002030-200204120-00021. AIDS. 2002. PMID: 11919503

5

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.

Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS. Hogg RS, et al. AIDS. 2002 May 3;16(7):1051-8. doi: 10.1097/00002030-200205030-00012. AIDS. 2002. PMID: 11953472

6

Prescribing practices in a population-based HIV postexposure prophylaxis program.

Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, Hogg RS. Braitstein P, et al. AIDS. 2002 May 3;16(7):1067-70. doi: 10.1097/00002030-200205030-00014. AIDS. 2002. PMID: 11953474

7

Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.

Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, O'Shaughnessy MV, Mo T, Piaseczny M, Montaner JS, Harrigan PR. Alexander CS, et al. Antivir Ther. 2002 Mar;7(1):31-5. Antivir Ther. 2002. PMID: 12008785

8

No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.

Brumme ZL, Chan KJ, Dong WW, Mo T, Wynhoven B, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. AIDS. 2002 Sep 27;16(14):1929-33. doi: 10.1097/00002030-200209270-00010. AIDS. 2002. PMID: 12351953

9

Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996.

Wood E, Montaner JS, Chan K, Tyndall MW, Schechter MT, Bangsberg D, O'Shaughnessy MV, Hogg RS. Wood E, et al. AIDS. 2002 Oct 18;16(15):2065-72. doi: 10.1097/00002030-200210180-00012. AIDS. 2002. PMID: 12370506

10

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.

Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. Brumme ZL, et al. AIDS. 2003 Jan 24;17(2):201-8. doi: 10.1097/00002030-200301240-00010. AIDS. 2003. PMID: 12545080

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

585 results

Search Page

Filters